Combination warfarin-ASA therapy: Which patients should receive it, which patients should not, and why?

Thrombosis Research

Volumn 127, Issue 6, 2011, Pages 513-517

  Douketis, James D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antiplatelet therapy; ASA; Combination warfarin ASA; Harm; Oral anticoagulants; Therapeutic benefit; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ACETYLSALICYLIC ACID PLUS WARFARIN; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; DABIGATRAN; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

ADD ON THERAPY; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; EVIDENCE BASED PRACTICE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; STROKE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ASPIRIN; COMBINED MODALITY THERAPY; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 79957598382     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.02.010     Document Type: Review

References (27)

1. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Anderson C, Jørgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374:1967-74.
2. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008;133(6 Suppl): 299S-339S.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
4. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-7.
5. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, et al. The primary and secondary prevention of coronary artery disease. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:776S-814S.
6. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation - executive summary. Circulation 2006;114:700-52.
7. Johnson SG, Witt DM, Eddy TR, Delate T. Warfarin and antiplatelet combination use among commercially insured patients enrolled in a anticoagulation management service. Chest 2007;131:1500-7. (Pubitemid 46762359)
8. Go AS, Hylek EM, Phillips JA, Chang YC, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001;285:2370-5. (Pubitemid 32424106)
9. National Heart, Lung and Blood Institute. Morbidity and mortality: 2007 Chart book on ardiovascular, lung, and blood disease. Bethesda, MD [available on-line at]http://www.nhlbi.nih.gov/resources/docs/cht-book.htm.
10. Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease. Arch Intern Med 2007;167:117-1241.
11. Van Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13. (Pubitemid 34786198)
12. Hurlen M, Abdelnoor M, Smith P, Erikssen J. Arnesen. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
13. Flacker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, et al. Risk and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006;152:967-73. (Pubitemid 44637136)
14. Johnson SG, Rogers K, Delate T, Witt DM. Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 2008;133:948-54. (Pubitemid 351536871)
15. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433-41.
16. ACTIVE Writing Group of the ACTIVE InvestigatorsConnolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.
17. Van der Meer FJM, Rosendaal FR, Van der Broucke JP, Briet E. Bleeding complications in oral anticoagulation therapy. Arch Intern Med 1993;153:1557-62.
18. Spencer FA, Gore JM, Lessard D, Douketis JD, Emery C, Goldberg RJ. Patient outcomes after deep vein thrombosis and pulmonary embolism: The Worcester Venous Thromboembolism Study. Arch Intern Med 2008;168:425-30. (Pubitemid 351347134)
19. Linkins LA, Choi P, Douketis JD. Clinical impact of Bleeding in patients taking oral anticoagulation therapy for venous thromboembolism: a meta analysis. Ann Intern Med 2003;139:893-900.
20. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010;152:578-89.
21. Amlani S, Nadarajah T, Afzal R, Pal-Sayal R, Eikelboom JW, Natarajan MK. Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. J Thromb Thrombolysis 2010;30:434-40.
22. Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009;120:2006-11.
23. Douketis J, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin. Arch Intern Med 2006;166:853-9.
24. Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:593S-629S.
25. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease - executive summary. Circulation 2006;114:450-527.
26. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. JAMA 2001;285:2864-70.
27. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 Suppl):670S-707S.